JW Shinyak said Thursday that it has entered a joint sales agreement with JW Pharmaceutical to market Johnson & Johnson’s (J&J) Rogaine (Ingredient: minoxidil), a hair loss treatment.
The company signed an exclusive distributorship contract to market the product with J&J in November. Under the new accord, JW Shinyak will focus on wholesale and distribution targeting pharmacies near private doctor’s offices, while JW Pharmaceutical will be responsible for marketing to direct transaction pharmacies.
Rogaine is the top-selling hair loss treatment and is also the first treatment of its kind to receive approval from the U.S. Food and Drug Administration (FDA).
The therapy is also the first foam hair loss treatment approved for sales in Korea. The foam form allows users to apply the proper amount to only the necessary part and is also quickly absorbed by the scalp and dries faster than conventional hair loss treatments.
The main ingredient, minoxidil, increases blood flow to the scalp, which in turn makes hair follicle healthy and lengthens hair growth cycle. This product also does not contain propylene glycol (PG) making it is less irritating to the scalp.
With the addition of Rogaine, JW Shinyak plans to create a synergy between the treatment and its other existing oral hair loss treatment such as Monad and Neodart.
“As the number of patients looking for Rogaine foam increased, the company needed a new to secure various distribution channels,” a company official said. “We will expand the supply of Rogaine nationwide by utilizing the over-the-counter (OTC) drug distribution network of JW Pharmaceutical."
<© Korea Biomedical Review, All rights reserved.>